Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers - PubMed (original) (raw)
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
A H Jan Danser et al. Hypertension. 2020 Jun.
Abstract
During the spread of the severe acute respiratory syndrome coronavirus-2, some reports of data still emerging and in need of full analysis indicate that certain groups of patients are at risk of COVID-19. This includes patients with hypertension, heart disease, diabetes mellitus, and clearly the elderly. Many of those patients are treated with renin-angiotensin system blockers. Because the ACE2 (angiotensin-converting enzyme 2) protein is the receptor that facilitates coronavirus entry into cells, the notion has been popularized that treatment with renin-angiotensin system blockers might increase the risk of developing a severe and fatal severe acute respiratory syndrome coronavirus-2 infection. The present article discusses this concept. ACE2 in its full-length form is a membrane-bound enzyme, whereas its shorter (soluble) form circulates in blood at very low levels. As a mono-carboxypeptidase, ACE2 contributes to the degradation of several substrates including angiotensins I and II. ACE (angiotensin-converting enzyme) inhibitors do not inhibit ACE2 because ACE and ACE2 are different enzymes. Although angiotensin II type 1 receptor blockers have been shown to upregulate ACE2 in experimental animals, the evidence is not always consistent and differs among the diverse angiotensin II type 1 receptor blockers and differing organs. Moreover, there are no data to support the notion that ACE inhibitor or angiotensin II type 1 receptor blocker administration facilitates coronavirus entry by increasing ACE2 expression in either animals or humans. Indeed, animal data support elevated ACE2 expression as conferring potential protective pulmonary and cardiovascular effects. In summary, based on the currently available evidence, treatment with renin-angiotensin system blockers should not be discontinued because of concerns with coronavirus infection.
Keywords: ACE inhibitor; COVID-19; angiotensin receptor blocker; coronavirus; severe acute respiratory syndrome.
Figures
Figure.
Overview of the connections between renin-angiotensin system blockers, ACE2 (angiotensin-converting enzyme 2) and the coronavirus. The carboxypeptidase ACE2 converts Ang II (angiotensin II) to Ang-(1–7) and Ang I to Ang-(1–9) (A), yet is not blocked by ACE (angiotensin-converting enzyme) inhibitors, which prevent the conversion of Ang I to Ang II. ACE2 also binds and internalizes SARS-Cov-2 (severe acute respiratory syndrome coronavirus-2; B), after priming by the serine protease TMPRSS2 (transmembrane protease, serine 2). Shedding of membrane-bound ACE2 by a disintegrin and metalloprotease 17 (ADAM17) results in the occurrence of soluble (s) ACE2, which can no longer mediate SARS-Cov-2 entry and which might even prevent such entry by keeping the virus in solution. AT1R (Ang II, via its type 1 receptor) upregulates ADAM17, and AT1R blockers (ARBs) would prevent this.
Comment in
- Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.
Zhou F, Liu YM, Xie J, Li H, Lei F, Yang H, Qin JJ, Cai J, Zhang XJ, Wu B, Xia M, Xiang D, Yang C, Ma X, Xu Q, Lu Z, Lu H, Xia X, Wang D, Liao X, Peng G, Yang J, Huang X, Zhang BH, Yuan Y, Wei X, Liu PP, Wang Y, Zhang P, She ZG, Xia J, Li H. Zhou F, et al. Hypertension. 2020 Aug;76(2):e15-e17. doi: 10.1161/HYPERTENSIONAHA.120.15622. Epub 2020 Jun 3. Hypertension. 2020. PMID: 32493070 No abstract available.
Similar articles
- Renin-angiotensin-aldosterone system and COVID-19 infection.
Alexandre J, Cracowski JL, Richard V, Bouhanick B; 'Drugs, COVID-19' working group of the French Society of Pharmacology, Therapeutics. Alexandre J, et al. Ann Endocrinol (Paris). 2020 Jun;81(2-3):63-67. doi: 10.1016/j.ando.2020.04.005. Epub 2020 Apr 21. Ann Endocrinol (Paris). 2020. PMID: 32370986 Free PMC article. Review. - [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
Kreutz R, Abd El-Hady Algharably E, Ganten D, Messerli F. Kreutz R, et al. Pneumologie. 2020 Sep;74(9):611-614. doi: 10.1055/a-1165-6994. Epub 2020 Sep 11. Pneumologie. 2020. PMID: 32916743 German. No abstract available. - Drugs acting on renin angiotensin system and use in ill patients with COVID-19.
Alexandre J, Cracowski JL, Richard V, Bouhanick B; French Society of Pharmacology and Therapeutics (SFPT). Alexandre J, et al. Therapie. 2020 Jul-Aug;75(4):319-325. doi: 10.1016/j.therap.2020.05.009. Epub 2020 May 20. Therapie. 2020. PMID: 32553503 Free PMC article. Review. - [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
Kreutz R, Abd El-Hady Algharably E, Ganten D, Messerli F. Kreutz R, et al. Dtsch Med Wochenschr. 2020 May;145(10):682-686. doi: 10.1055/a-1152-3469. Epub 2020 Apr 22. Dtsch Med Wochenschr. 2020. PMID: 32323279 Free PMC article. Review. German. - Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.
Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, Raizada MK, Grant MB, Oudit GY. Gheblawi M, et al. Circ Res. 2020 May 8;126(10):1456-1474. doi: 10.1161/CIRCRESAHA.120.317015. Epub 2020 Apr 8. Circ Res. 2020. PMID: 32264791 Free PMC article. Review.
Cited by
- COVID-19 and chronic kidney disease: a comprehensive review.
Pecly IMD, Azevedo RB, Muxfeldt ES, Botelho BG, Albuquerque GG, Diniz PHP, Silva R, Rodrigues CIS. Pecly IMD, et al. J Bras Nefrol. 2021 Jul-Sep;43(3):383-399. doi: 10.1590/2175-8239-JBN-2020-0203. J Bras Nefrol. 2021. PMID: 33836039 Free PMC article. Review. - Personal and vaccination history as factors associated with SARS-CoV-2 infection.
Fernández-Prada M, García-González P, García-Morán A, Ruiz-Álvarez I, Ramas-Diez C, Calvo-Rodríguez C. Fernández-Prada M, et al. Med Clin (Barc). 2021 Sep 10;157(5):226-233. doi: 10.1016/j.medcli.2021.02.011. Epub 2021 Mar 19. Med Clin (Barc). 2021. PMID: 33966881 Free PMC article. English, Spanish. - Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19.
Khan SH, Zaidi SK. Khan SH, et al. Drugs Ther Perspect. 2020;36(8):347-350. doi: 10.1007/s40267-020-00750-w. Epub 2020 Jun 9. Drugs Ther Perspect. 2020. PMID: 32837189 Free PMC article. - Intrinsic disorder perspective of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2.
Elrashdy F, Redwan EM, Uversky VN. Elrashdy F, et al. Infect Genet Evol. 2020 Nov;85:104510. doi: 10.1016/j.meegid.2020.104510. Epub 2020 Aug 24. Infect Genet Evol. 2020. PMID: 32853823 Free PMC article. Review. - Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 - can we end this viral series?
Cismaru AC, Cismaru LG, Nabavi SF, Berindan-Neagoe I, Clementi E, Banach M, Nabavi SM. Cismaru AC, et al. Arch Med Sci. 2020 Jun 27;17(2):275-284. doi: 10.5114/aoms.2020.96604. eCollection 2021. Arch Med Sci. 2020. PMID: 33747262 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous